Physician profile
Julia T Donovan
NPI 1104892157
$282.82
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $77.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.67 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.12 | 2019 | |
| Astellas Pharma US INC | $16.76 | 2019 | |
| Exelixis INC. | $16.53 | 2019 | |
| Amgen INC. | $16.20 | 2019 | |
| Janssen Biotech, INC. | $15.20 | 2019 | |
| Array Biopharma INC | $14.24 | 2019 | |
| Rigel Pharmaceuticals, INC. | $13.33 | 2019 | |
| Merck Sharp & Dohme LLC | $12.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.